Who is sponsoring NCT04484506?

NCT04484506 is sponsored by Peking University.

What drugs are being tested in NCT04484506?

Interventions in NCT04484506: pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone.

What condition does NCT04484506 study?

NCT04484506 studies NK/T Cell Lymphoma Nos.

Is NCT04484506 still recruiting?

NCT04484506 is currently status unknown. Last updated 23 July 2020.

Last reviewed 2020-07-23 · How we verify

NCT04484506

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma

Status unknown Phase 2 Last updated 23 July 2020

What this trial tests

Phase 2 trial testing pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone in NK/T Cell Lymphoma Nos in 150 participants. Status unknown.

Timeline

20 October 2011

Primary endpoint
30 December 2023

30 December 2025

Quick facts

Lead sponsor	Peking University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	20 October 2011
Primary completion	30 December 2023
Estimated completion	30 December 2025
Sites	1 location across China

Drugs / interventions tested

pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone — full drug profile →

Conditions studied

NK/T Cell Lymphoma Nos — all drugs for NK/T Cell Lymphoma Nos →

Sponsor

Peking University

Who can join

Adults 14 to 80, any sex, with NK/T Cell Lymphoma Nos. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been well-defined. This phase II study aimed to evaluate the efficacy and safety of pegaspargase, cyclophosphamide, vincristine, etoposide and prednisone (COEPL) regimen combined with radiotherapy for patients with newly diagnosed ENKTL.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The contemporary management of cancers of the sinonasal tract in adults.
Thawani R, Kim MS, Arastu A, Feng Z, et al · · 2023 · cited 95× · PMID 35916666 · DOI 10.3322/caac.21752
Targeting Autophagy with Natural Products as a Potential Therapeutic Approach for Cancer.
Al-Bari MAA, Ito Y, Ahmed S, Radwan N, et al · · 2021 · cited 34× · PMID 34575981 · DOI 10.3390/ijms22189807

Verify or expand the search:

Other recruiting trials for NK/T Cell Lymphoma Nos

Currently open trials in the same condition.

NCT04365036 — A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in · Phase 3 · recruiting
NCT04127227 — Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type · Phase 2 · active not recruiting

Other Peking University trials

Trials by the same sponsor.

NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04484506 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University
Last refreshed: 23 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04484506.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing